報價延遲最少15分鐘:2025/02/22 11:19 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.74 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.45/2.85
|
|
企業價值
35.78B
|
| 資產負債 |
|
每股賬面淨值
4.69
|
| 現金流量 |
|
現金流量率
0.06
|
| 損益表 |
|
收益
16.54B
|
|
每股收益
13.11
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/22 11:19 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor. |